CRISPA: A Non-viral, Transient Cas9 Delivery System Based on Reengineered Anthrax Toxin

Translating the CRISPR/Cas9 genome editing technology into clinics is still hampered by rather unspecific, unsafe and/or inconvenient approaches for the delivery of its main components - the Cas9 endonuclease and a guide RNA - into cells. Here, we describe the development of a novel transient and no...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirschenberger, Maximilian, Stadler, Nicole, Fellermann, Maximilian, Sparrer, Konstantin M. J., Kirchhoff, Frank, Barth, Holger, Papatheodorou, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558532/
https://www.ncbi.nlm.nih.gov/pubmed/34733166
http://dx.doi.org/10.3389/fphar.2021.770283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558532/
https://www.ncbi.nlm.nih.gov/pubmed/34733166
http://dx.doi.org/10.3389/fphar.2021.770283

Ejemplares similares